$1,000 in Nvidia vs. $1,000 in Broadcom: Which AI Chip Bet Paid Off More?

The article compares Nvidia vs. Broadcom for AI-chip exposure, noting $1,000 invested mid-2021 would be ~$10,100 in Nvidia vs ~$9,100 in Broadcom over five years, but over the last 12 months Broadcom led (~$1,440 vs ~$1,280). Nvidia reported record quarterly revenue of $81.6B (+85% YoY; data center $75.2B, +92% YoY) and is described as trading at ~20x forward earnings (cheaper than Broadcom at ~25x). Despite Broadcom’s faster AI growth (AI revenue $10.8B, +143% YoY; ~$16B guided for the quarter), the author argues Nvidia offers the better forward mix of faster growth at the lower multiple for a fresh $1,000 allocation.

Analysis

This is less a fundamental downgrade of either business than a relative-value reset inside the AI complex. NVDA looks like the cleaner beta to continued hyperscaler capex: if AI budgets stay intact, investors should prefer the name with the broader customer set, higher operating leverage, and lower multiple. AVGO’s edge is durability, not speed; its software and custom-silicon mix reduces downside, but that also means it should not command a premium if the market is paying for AI growth duration.

The key second-order effect is competitive substitution. If large cloud buyers keep pushing custom ASICs and networking silicon, AVGO can keep taking share in a narrower lane even if GPU demand remains healthy. If, however, capex broadens beyond a few platforms and the build-out remains training-heavy, NVDA benefits from being the default “pick-and-shovel” exposure while AVGO looks more like a concentrated infrastructure lever.

Catalyst path: over the next 1-3 months, relative performance will likely be driven by hyperscaler capex commentary, margin guidance, and any evidence that custom chips are cannibalizing accelerators faster than expected. The main falsifier for the NVDA-over-AVGO view is a guide-down tied to supply normalization or a sharper-than-expected shift toward in-house silicon. The contrarian point is that AVGO’s diversification may deserve the premium in a late-cycle AI spend environment; the market may be underpricing how quickly concentration risk can turn into an earnings support feature.

Key Decisions for Investors

• Long NVDA / short AVGO as a 3-6 month relative-value pair on any 5-7% NVDA pullback; thesis is lower forward multiple plus broader AI beta versus AVGO's concentration premium. Exit if AVGO re-accelerates AI revenue growth faster than NVDA guides or if NVDA margins compress.
• If needing a lower-risk expression, buy NVDA call spreads into the next earnings cycle rather than outright equity; the setup is for multiple re-rating, not just earnings beats. Falsify on any guidance that implies AI demand normalization.
• Use AVGO as a defensive AI hedge only if you expect capex deceleration over the next 6-12 months; otherwise avoid paying a premium multiple for the diversified name when the market is rewarding growth duration.
• Watch hyperscaler capex and custom-ASIC disclosures as the real catalyst set; if those show broadening spend rather than substitution, increase NVDA exposure and reduce AVGO relative weight.